The clinical relevance of SETD2 in cancer, along with the lack of further inhibitor chemotypes and the general ADME/bioavailability concerns around nucleoside analogs (such as sinefungin), prompted us to launch a virtual screening campaign with the aim of identifying small molecule inhibitors of SETD2 with novel chemical scaffolds. Here, SETD2 is linked to cancer.